ESTRO 2023 - Abstract Book

S1219

Digital Posters

ESTRO 2023

§ data available for five out of six patients; * data available for six out of ten patients.

Conclusion To the best of our knowledge, we reported the first cohort of frail and elderly BC patients treated with SBRT to the GT and to the tumor bed after TURBT. Our preliminary data demonstrate that the treatment is technically feasible, with an acceptable toxicity profile. In this underrepresented setting of patients more solid indications are required based on further and updated FU data on toxicities and oncological outcomes.

PO-1501 HERMES: Are we delivering?

R. Westley 1,5 , A. Dunlop 2 , A. Mitchell 2 , S. Diamantopoulos 2 , S. Alexander 3,4 , T. Herbert 3 , J. Mohajer 2 , U. Oelfke 2 , A. Tree 5,1

1 The Royal Marsden NHS Foundation Trust, Uro-oncology, Sutton, United Kingdom; 2 Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Physics, Sutton, United Kingdom; 3 The Royal Marsden NHS Foundation Trust, Radiotherapy, Sutton, United Kingdom; 4 The Institute of Cancer Research, Radiotherapy, Sutton, United Kingdom; 5 The Institute of Cancer Research, Uro-oncology, Sutton, United Kingdom Purpose or Objective HERMES (NCT04595019) is a novel phase II randomised trial of ultra-hypofractionated stereotactic body radiotherapy (SBRT) in men with localised prostate cancer (1). Treatment is delivered on The Elekta Unity MR-Linac (Elekta AB, Stockholm) a hybrid of a 1.5 Tesla Philips MR and 7MV FFF linear accelerator that enables online adaptive and precise radiotherapy delivery (2). HERMES randomises between 2 fraction and 5 fraction SBRT2. It opened in September 2021 at The Royal Marsden, with a recruitment target of 46 participants. Figure 1 shows the HERMES trial schematic. Trial outcomes are collected within the MOMENTUM database (3).